Rubius Exec Dowden Departs for Entrada Chief Operating Officer Post
Entrada Therapeutics has appointed Nathan Dowden to serve as its chief operating officer. He joins Boston-based Entrada from Rubius Therapeutics, where he was senior vice president of strategy and corporate development. Entrada is developing drugs that that use cell-penetrating peptides to bring a therapy into a cell. Last year, the biotech raised $59 million in Series A financing.
More from EXOME
Trending on Xconomy
Underwriters and Partners
Xpertise: Watch + Learn
From Our Editors · Special Report
2019 Biopharma Outlook – Facing an Uncertain Future
Key indicators & expert insight from industry leaders
Xconomy
From Our Partners · Special Report
Robert Langer reveals secrets to early-stage biotech success
Advice for funding and future transformational opportunities
Xconomy Insight · Webinar
Digital Healthcare Revolution Webinar Series
AI, drug discovery and development, IBM Watson Health, oncology, genomics & more